Guidelines for the Diagnosis and Management of von Willebrand Disease
These guidelines were completed in 2021 as a collaboration between The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (1ST H), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) and are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis and management. There are recommendations relating to guidance on prophylaxis, major and minor surgeries, heavy menstrual and postpartum bleeding, diagnostic thresholds, genetic testing, and much more. These guidelines are also a valuable resource for shared decision-making discussions between healthcare providers and people with VWD, as well as for advocacy activities to improve access to the recommended diagnostic techniques and treatment options in all countries.
VWD Guidelines Methodology
ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that included 4 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical Center (KUMC) supported the guideline-development process, including performing or updating systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently subject to public comment. For more methodological details refer to the [publication].
ASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. For more methodological details refer to the [publication].
How to Cite these Guidelines (APA Style)
James, P. D. , Connell, N. T., Ameer, B., Paola, J. D., Eikenboom, J., Giraud, N., Haberichter, S., Jacobs-Pratt, V., Konkle, B., McLintock, C., McRae, S., Montgomery, R. R., O’Donnell, J. S., Scappe, N., Sidonio, R., Flood, V. H., Husainat, N., Kalot, M. A. & Mustafa, R. A. (2021). ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 5(1), 280—300. https;
Connell, N. T., Flood, V. H., Brignardello-Petersen, R., Abdul-Kadir, R., Arapshian, A., Couper, S., Grow, J. M., Kouides, P., Laffan, M., Lavin, M., Leebeek, F. W. G., O’Brien, S. H.. Ozelo, M. C., Tosetto, A., Weyand, A. C., James, P. D., Kalot, M. A., Husainat, N. & Mustafa, R. A. (2021). ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 5(1), 301—325. https;[(doj.org/l Q. 1182/bIoodadvances.2020003264
